PREGNANT (Mammakarzinom) Prospektives akademisches translationales Forschungsnetzwerk zur Optimierung der onkologischen Versorgungsqualität in der adjuvanten und fortgeschrittenen metastasierten Situation

PRAEGNANT - Prospective Academic translational research network for the optimization of oncological health care quality in the advanced setting. This german study network was set up to take account of some of the recent developments in molecular medicine in the treatment of patients with metastatic breast cancer.

It is an academic registry and translational diagnostics study with the aim to build a healthcare research data base with the objective:

• to carry out molecular tests under study conditions
• to identify suitable breast cancer patients for clinical trials based on molecular testing
• to identify breast cancer patients suitable for clinical trials based on conventional inclusion criteria
• to record treatment-induced toxicities and patient´s quality of life in routine clinical practice
• to record, show and benchmark the reality of medical care provided to patients with advanced/metastatic breast cancer

PRAEGNANT is subdivided into three main phases. In phase I, only advanced breast cancer patients are included. In phases II and III the data base should be expanded by (neo-)adjuvant breast cancer patients and in the end by other tumor entities.

Patient information
If you are interested to take part in the study. Please don´t hesitate to contact a study center in your vicinity.
Some fundamental backgrund information:

• your peronal data will be treated confidentially and are transferred anonimysed
• you are asked to give a blood sample, which is needed for biomarker detection
• the achieved therapy successes in this study will help to improve breast cancer treatment
• to record treatment-induced toxicities and patient´s quality of life in routine clinical practice
• to record, show and benchmark the reality of medical care provided to patients with advanced/metastatic breast cancer

What´s your benefit?
Your personal biomarker profile will be given to your treating phyisician, if you wish so. Then your treatment may be changed or you can be introduced in other clinical studies which show a good prognosis according to your biomarker profile.
All treatements and collected data will be treated confidentially.